# A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

> **NCT03915379** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 68 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** JNJ-67571244

## Key facts

- **NCT ID:** NCT03915379
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2022-03-26
- **Final completion:** 2022-03-28
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915379, "A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03915379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*